Developer docs
API playgroundTry for free, no card

Search company profiles

Pinnacle Clinical Research

Full company profile

uuid000811u

Namestring
Pinnacle Clinical Research
Legal namestring
Pinnacle Clinical Research
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Pinnacle Clinical Research (PCR) is a privately held, PE-backed multi-site clinical research site network founded in 2016 by Dr. Stephen Harrison and headquartered in San Antonio, Texas. The company operates 15 fully owned research sites across Texas, New Jersey, and Nevada, conducting clinical trials in complex therapeutic areas including Steatotic Liver Disease (MASLD/MASH), CNS/Alzheimer's disease, cardiometabolic disorders, and obesity on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). Its core differentiator is therapeutic specialization — the network is built around specialized diagnostic infrastructure including FibroScan (vibration-controlled transient elastography), quantitative liver MRI with PDFF/MRE/cT1 capabilities, CDR-certified neurocognitive raters, and dedicated infusion suites — and access to diverse, bilingual patient populations, particularly Hispanic communities in South Texas. Pinnacle consistently ranks among the top global enrollers for MASH trials and reports operational metrics of sub-30-day trial activation, 48-hour contract/budget response turnaround, and 70–90%+ patient retention across longitudinal trials.

The company's business model is professional-services based: it contracts with pharmaceutical sponsors and CROs for trial execution and generates revenue through study enrollment, patient management, and data delivery across its site network. Patient recruitment flows from physician referral networks (with formal fax/EMR-based referral programs), community outreach with bilingual support, and direct patient engagement via free FibroScan liver screening and memory screening services. Pricing is not publicly disclosed; clinical trial participation is provided at no cost to patients, with all revenue contracted between Pinnacle and its sponsor/CRO clients.

Growth has been driven by a PE-backed roll-up strategy under LongueVue Capital Partners, which installed operating partner Adrian Otte as CEO. Between 2022 and 2024 the network expanded from 5 to 13 wholly owned sites through five add-on acquisitions — including South Texas Research Institute, The Cognitive and Research Center of New Jersey, Kerwin Medical Center, Bellaire Clinical Research, and Jubilee Clinical Research — broadening therapeutic breadth from liver disease into CNS/Alzheimer's, cardiometabolic, and obesity. In late 2024, founding STRI CEO Dr. Rashmee Patil transitioned to the Chief Medical Officer role, completing a leadership professionalization consistent with institutional scaling.

Short descriptiontext

Pinnacle Clinical Research is a PE-backed, multi-site clinical research site network operating 15 fully owned sites across Texas, New Jersey, and Nevada, conducting clinical trials in hepatology, CNS/Alzheimer's, cardiometabolic, and obesity for pharmaceutical sponsors and CROs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices14 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, hepatology clinical trials, MASH clinical trials, Alzheimer's research trials, clinical site network
Industry3 codes
PRIMARYHLAKAEAL
Liver & GI Clinical Research (Trials Centers)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Contract Research
TypeProfessional Services
Description

Pinnacle conducts clinical trials on behalf of pharmaceutical sponsors and CROs. Revenue is generated through contracted research agreements for study execution, patient enrollment, and data collection across their site network. The company has grown through M&A consolidation of clinical research sites.

pinnacleresearch.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pinnacle Clinical Research operates a network of 15 fully owned clinical research sites across the United States that conduct clinical trials on behalf of pharmaceutical sponsors and CROs. The company specializes in complex therapeutic areas including Steatotic Liver Disease (MASLD/MASH), CNS/Alzheimer's disease, cardiometabolic disorders, and obesity, providing study startup, patient enrollment, site management, and data collection services. It also offers free FibroScan liver diagnostics and memory screening programs to support patient identification and recruitment across its site network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 48-hour turnaround on initial contract/budget response; 7-10 business days from receipt to execution
+4 more records
Product overview1 text field

Pinnacle Clinical Research operates as a premier multi-site clinical research network offering integrated research services across multiple therapeutic areas. The company's portfolio includes its core clinical trial site network of 15 wholly-owned locations across Texas, New Jersey, Nevada, and California, supported by specialized diagnostic services including FibroScan® liver diagnostics and memory screening programs. The network focuses on complex therapeutic areas including Steatotic Liver Disease (SLD/MASH), CNS/Alzheimer's disease, Cardiometabolic disorders, and Obesity, providing sponsors with rapid study startup, top-tier enrollment, and access to diverse, research-ready patient populations. The company offers centralized operations, therapeutic expertise, and scalable footprint to ensure trials are executed with precision and speed, with trial activation typically under 30 days.

Product and service6 records
1Clinical Trial Site Network
CategoryClinical Trial Site Network
2SLD/MASH Clinical Trials
CategoryTherapeutic Area Clinical Trials
3CNS/Alzheimer's Disease Clinical Trials
CategoryTherapeutic Area Clinical Trials
4Cardiometabolic Disorders Clinical Trials
CategoryTherapeutic Area Clinical Trials
5Obesity Clinical Trials
CategoryTherapeutic Area Clinical Trials
6FibroScan Liver Diagnostic Services
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1South Texas Research Institute (STRI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

South Texas Research Institute partnered with Pinnacle Clinical Research in 2022. Dr. Rashmee Patil, Founder of STRI, served as CEO of the combined entity from 2022-2024. STRI grew from one site and five employees in 2020 to 2 locations and over 30 team members before the partnership. During Dr. Patil's leadership, Pinnacle grew from 5 to 13 wholly owned sites.

pinnacleresearch.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founded by Dr. Mazen Noureddin, Chief Science Officer and Co-Chairman of the Board at Pinnacle. Houston Research Institute is a state-of-the-art clinical research facility focused on advancing innovative diagnostics and breakthrough therapies in liver disease, now part of the Pinnacle network.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Private equity-backed (Gryphon Investors) network of wholly owned clinical research sites across the U.S. Like Pinnacle, Velocity consolidates fragmented sites via M&A, executes multi-therapeutic trials, and competes for the same sponsor and CRO RFPs.

TypeDirect peer
Description

Texas-based multi-site clinical research network with therapeutic breadth across internal medicine, endocrinology, and women's health. Directly comparable in scale, operating model (wholly owned sites), and sponsor/CRO customer base to Pinnacle.

TypeDirect peer
Description

Clinical research site network that integrates community-based physicians into trials. Pinnacle's COO Eli Alford previously served as Elligo's COO, evidencing direct operational comparability and talent pipeline overlap.

5Accelerated Enrollment Solutions (AES)
TypeDirect peer
Description

PPD's (now Thermo Fisher Scientific) dedicated patient enrollment site network focused on accelerated startup and enrollment. Competes with Pinnacle for the same multi-therapeutic sponsor studies, particularly in primary care and specialty indications.

TypeBroad incumbent
Description

Largest global CRO with an integrated site network and decentralized trial capabilities. Competes for sponsor site-network RFPs and offers end-to-end clinical development services well beyond Pinnacle's site-only scope.

TypeOthers
Description

Large biopharmaceutical solutions organization combining CRO services with a clinical site network. Overlaps with Pinnacle on site-level trial execution while offering full-service clinical development to sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pinnacle Clinical Research

Clinical Research Servicespinnacleresearch.com

Pinnacle Clinical Research is a PE-backed, multi-site clinical research site network operating 15 fully owned sites across Texas, New Jersey, and Nevada, conducting clinical trials in hepatology, CNS/Alzheimer's, cardiometabolic, and obesity for pharmaceutical sponsors and CROs.

What Pinnacle Clinical Research does

Pinnacle Clinical Research (PCR) is a privately held, PE-backed multi-site clinical research site network founded in 2016 by Dr. Stephen Harrison and headquartered in San Antonio, Texas. The company operates 15 fully owned research sites across Texas, New Jersey, and Nevada, conducting clinical trials in complex therapeutic areas including Steatotic Liver Disease (MASLD/MASH), CNS/Alzheimer's disease, cardiometabolic disorders, and obesity on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). Its core differentiator is therapeutic specialization — the network is built around specialized diagnostic infrastructure including FibroScan (vibration-controlled transient elastography), quantitative liver MRI with PDFF/MRE/cT1 capabilities, CDR-certified neurocognitive raters, and dedicated infusion suites — and access to diverse, bilingual patient populations, particularly Hispanic communities in South Texas. Pinnacle consistently ranks among the top global enrollers for MASH trials and reports operational metrics of sub-30-day trial activation, 48-hour contract/budget response turnaround, and 70–90%+ patient retention across longitudinal trials.

The company's business model is professional-services based: it contracts with pharmaceutical sponsors and CROs for trial execution and generates revenue through study enrollment, patient management, and data delivery across its site network. Patient recruitment flows from physician referral networks (with formal fax/EMR-based referral programs), community outreach with bilingual support, and direct patient engagement via free FibroScan liver screening and memory screening services. Pricing is not publicly disclosed; clinical trial participation is provided at no cost to patients, with all revenue contracted between Pinnacle and its sponsor/CRO clients.

Growth has been driven by a PE-backed roll-up strategy under LongueVue Capital Partners, which installed operating partner Adrian Otte as CEO. Between 2022 and 2024 the network expanded from 5 to 13 wholly owned sites through five add-on acquisitions — including South Texas Research Institute, The Cognitive and Research Center of New Jersey, Kerwin Medical Center, Bellaire Clinical Research, and Jubilee Clinical Research — broadening therapeutic breadth from liver disease into CNS/Alzheimer's, cardiometabolic, and obesity. In late 2024, founding STRI CEO Dr. Rashmee Patil transitioned to the Chief Medical Officer role, completing a leadership professionalization consistent with institutional scaling.

Pinnacle Clinical Research firmographics

Firmographics
Name
Pinnacle Clinical Research
Legal name
Pinnacle Clinical Research
Website
https://pinnacleresearch.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Pinnacle Clinical Research is a PE-backed, multi-site clinical research site network operating 15 fully owned sites across Texas, New Jersey, and Nevada, conducting clinical trials in hepatology, CNS/Alzheimer's, cardiometabolic, and obesity for pharmaceutical sponsors and CROs.
Ownership category
akta.pro rank

Pinnacle Clinical Research industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAEAL
Liver & GI Clinical Research (Trials Centers)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)

Keywords

  • Clinical research services
  • Hepatology clinical trials
  • MASH clinical trials
  • Alzheimer's research trials
  • Clinical site network

Where Pinnacle Clinical Research is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Offices14 records

Markets served

Pinnacle Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Clinical Trial Contract Research: Pinnacle conducts clinical trials on behalf of pharmaceutical sponsors and CROs. Revenue is generated through contracted research agreements for study execution, patient enrollment, and data collection across their site network. The company has grown through M&A consolidation of clinical research sites.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Pinnacle Clinical Research product offering

Product offering

Core offering

Pinnacle Clinical Research operates a network of 15 fully owned clinical research sites across the United States that conduct clinical trials on behalf of pharmaceutical sponsors and CROs. The company specializes in complex therapeutic areas including Steatotic Liver Disease (MASLD/MASH), CNS/Alzheimer's disease, cardiometabolic disorders, and obesity, providing study startup, patient enrollment, site management, and data collection services. It also offers free FibroScan liver diagnostics and memory screening programs to support patient identification and recruitment across its site network.

Product overview

Pinnacle Clinical Research operates as a premier multi-site clinical research network offering integrated research services across multiple therapeutic areas. The company's portfolio includes its core clinical trial site network of 15 wholly-owned locations across Texas, New Jersey, Nevada, and California, supported by specialized diagnostic services including FibroScan® liver diagnostics and memory screening programs. The network focuses on complex therapeutic areas including Steatotic Liver Disease (SLD/MASH), CNS/Alzheimer's disease, Cardiometabolic disorders, and Obesity, providing sponsors with rapid study startup, top-tier enrollment, and access to diverse, research-ready patient populations. The company offers centralized operations, therapeutic expertise, and scalable footprint to ensure trials are executed with precision and speed, with trial activation typically under 30 days.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trial Site Network
  • SLD/MASH Clinical Trials
  • CNS/Alzheimer's Disease Clinical Trials
  • Cardiometabolic Disorders Clinical Trials
  • Obesity Clinical Trials
  • FibroScan Liver Diagnostic Services

Quantifiable outcome

  • 48-hour turnaround on initial contract/budget response; 7-10 business days from receipt to execution
  • +4 more outcomes

Companies that use Pinnacle Clinical Research

Customer profile

Segments3 records

Ideal customer profiles2 records

Pinnacle Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Pinnacle Clinical Research partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • South Texas Research Institute (STRI)coreStrategic or Co-development PartnerSouth Texas Research Institute partnered with Pinnacle Clinical Research in 2022. Dr. Rashmee Patil, Founder of STRI, served as CEO of the combined entity from 2022-2024. STRI grew from one site and five employees in 2020 to 2 locations and over 30 team members before the partnership. During Dr. Patil's leadership, Pinnacle grew from 5 to 13 wholly owned sites.
  • Houston Research InstitutecoreStrategic or Co-development PartnerFounded by Dr. Mazen Noureddin, Chief Science Officer and Co-Chairman of the Board at Pinnacle. Houston Research Institute is a state-of-the-art clinical research facility focused on advancing innovative diagnostics and breakthrough therapies in liver disease, now part of the Pinnacle network.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Pinnacle Clinical Research competitors and assessment

Company assessment

Peers

Direct peers

  • Velocity Clinical Research: Private equity-backed (Gryphon Investors) network of wholly owned clinical research sites across the U.S. Like Pinnacle, Velocity consolidates fragmented sites via M&A, executes multi-therapeutic trials, and competes for the same sponsor and CRO RFPs.
  • DM Clinical Research: Texas-based multi-site clinical research network with therapeutic breadth across internal medicine, endocrinology, and women's health. Directly comparable in scale, operating model (wholly owned sites), and sponsor/CRO customer base to Pinnacle.
  • Elligo Health Research: Clinical research site network that integrates community-based physicians into trials. Pinnacle's COO Eli Alford previously served as Elligo's COO, evidencing direct operational comparability and talent pipeline overlap.
  • Accelerated Enrollment Solutions (AES): PPD's (now Thermo Fisher Scientific) dedicated patient enrollment site network focused on accelerated startup and enrollment. Competes with Pinnacle for the same multi-therapeutic sponsor studies, particularly in primary care and specialty indications.

Broad incumbents

  • IQVIA: Largest global CRO with an integrated site network and decentralized trial capabilities. Competes for sponsor site-network RFPs and offers end-to-end clinical development services well beyond Pinnacle's site-only scope.

Others

  • Syneos Health: Large biopharmaceutical solutions organization combining CRO services with a clinical site network. Overlaps with Pinnacle on site-level trial execution while offering full-service clinical development to sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Pinnacle Clinical Research social profiles

Digital presence

Pinnacle Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pinnacle Clinical Research leadership team

Management profile

Number of profiles

Profiles12 records

Pinnacle Clinical Research subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Pinnacle Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pinnacle Clinical Research M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pinnacle Clinical Research

What does Pinnacle Clinical Research do?

Pinnacle Clinical Research operates a network of 15 fully owned clinical research sites across the United States that conduct clinical trials on behalf of pharmaceutical sponsors and CROs. The company specializes in complex therapeutic areas including Steatotic Liver Disease (MASLD/MASH), CNS/Alzheimer's disease, cardiometabolic disorders, and obesity, providing study startup, patient enrollment, site management, and data collection services. It also offers free FibroScan liver diagnostics and memory screening programs to support patient identification and recruitment across its site network.

Is Pinnacle Clinical Research a public or private company?

Pinnacle Clinical Research is a private company. It is classified as private equity controlled and is currently operating.

When was Pinnacle Clinical Research founded?

Pinnacle Clinical Research was founded in 2016. It employs 101 to 250 people.

Where is Pinnacle Clinical Research based?

Pinnacle Clinical Research is headquartered in San Antonio, United States, in the North America region.

How does Pinnacle Clinical Research make money?

One revenue line is on record: clinical Trial Contract Research.

Who are Pinnacle Clinical Research's main competitors?

ICON plc is listed as a peer. Direct peers are Velocity Clinical Research, DM Clinical Research, Elligo Health Research and Accelerated Enrollment Solutions (AES). IQVIA is listed as a broad incumbent. Syneos Health is listed as an others.

Does Pinnacle Clinical Research have an API?

No public API is recorded for Pinnacle Clinical Research.

What industry is Pinnacle Clinical Research in?

Pinnacle Clinical Research's product category is Clinical Research Services. Its primary akta.pro industry code is HLAKAEAL, Liver & GI Clinical Research (Trials Centers), with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSUMMIT CLINICAL RESEARCH SOLUTIONS EXPANDS PINNACLE SITE NETWORK WITH ACQUISITION OF DALLAS RESEARCH INSTITUTESummit Clinical Research Solutions acquired Dallas Research Institute through its Pinnacle site network, expanding its Dallas-Fort Worth presence. DRI specializes in metabolic and liver disease trials, including MASLD and MASH, and was founded in 2024. The acquisition aligns with Summit's therapeutic expertise and adds a high-quality site in a strategic market.PR NewswireSummit Clinical Research and Pinnacle Clinical Research Unite as Summit Clinical Research Solutions, Creating a Fully Integrated Clinical Research PlatformSummit Clinical Research Solutions unified Summit Clinical Research and Pinnacle Clinical Research under one master brand, creating an integrated clinical research organization. The combined entity offers five platforms, with affiliated sites accounting for about 25% of trial sites and over 40% of enrolled patients. Since 2018, Summit has supported over 50 sponsors across 115 clinical trials.LvcpartnersLongueVue Capital Expands Pinnacle Clinical Research Platform with Acquisition of Jubilee Clinical ResearchLongueVue Capital's portfolio company, Pinnacle Clinical Research, has acquired Jubilee Clinical Research, a Las Vegas-based clinical trial site. This strategic acquisition expands Pinnacle's geographic footprint to the West Coast and enhances its expertise in metabolic and cardiovascular diseases.PR NewswireLONGUEVUE CAPITAL EXPANDS PINNACLE CLINICAL RESEARCH PLATFORM WITH ACQUISITION OF JUBILEE CLINICAL RESEARCHPinnacle Clinical Research, a portfolio company of LongueVue Capital, has acquired Jubilee Clinical Research, a Las Vegas-based clinical trial site organization. This strategic acquisition expands Pinnacle's geographic footprint to the West Coast and enhances its expertise in metabolic and cardiovascular diseases through Jubilee's established therapeutic focus and pharmaceutical relationships.PestakeholderPrivate Equity Health Care Acquisitions – June 2024The Private Equity Stakeholder Project tracked 73 private equity healthcare deals in June 2024, comprising 12 buyouts, 34 add-on acquisitions, and 27 growth/expansion investments. Notable transactions include Vista Equity Partners' approximately $1.25 billion public-to-private acquisition of revenue cycle management company Model N, and LongueVue Capital-backed Pinnacle Clinical Research expanding to 12 locations through five add-on acquisitions focused on clinical trials including central nervous system and Alzheimer's research. The article highlights accelerating consolidation trends in revenue cycle management (estimated $96.8 billion global market in 2022, projected to reach $238.4 billion by 2030) and clinical research, where private equity roll-up strategies are consolidating a highly fragmented industry.YahooPINNACLE CLINICAL RESEARCH ACCELERATES ITS RAPID EXPANSION WITH MULTIPLE ACQUISITIONS AND STRATEGIC PARTNERSHIPSPinnacle Clinical Research completed acquisitions of Kerwin Medical Center, CRCNJ, Bellaire, Palmetto, and DRI, expanding its network to twelve U.S. sites. The KMC and CRCNJ deals add CNS expertise, including Alzheimer's Disease focus. The company aims to broaden its scope and clinical proficiency.PR NewswirePinnacle Clinical Research Statement on Founder and Chairman Dr. Stephen HarrisonPinnacle Clinical Research announced the death of its Founder and Chairman, Dr. Stephen Harrison, who passed away on April 25, 2024. Dr. Harrison was a renowned hepatologist who pioneered liver research over a 30-year career, publishing over 350 peer-reviewed articles and playing an instrumental role in developing the first FDA-approved drug to treat MASH/MASLD. The company's CEO stated that Pinnacle remains committed to continuing Dr. Harrison's vision of building a multi-therapeutic site network.PR NewswirePINNACLE CLINICAL RESEARCH, A LONGUEVUE CAPITAL PORTFOLIO COMPANY, COMPLETES COMBINATION WITH SOUTH TEXAS RESEARCH INSTITUTEPinnacle Clinical Research announced its successful combination with South Texas Research Institute on January 10, 2023. The merger expands Pinnacle's network to six dedicated sites, enhancing diversity in patient recruitment, particularly among historically underrepresented populations. This move is anticipated to strengthen Pinnacle's position in the sector of complex indications such as non-alcoholic fatty liver disease and nonalcoholic steatohepatitis.PR NewswireLONGUEVUE CAPITAL COMPLETES INVESTMENT IN PINNACLE CLINICAL RESEARCH, LLCLongueVue Capital has completed an investment in Pinnacle Clinical Research, LLC, a multi-location clinical trial site organization specializing in complex therapeutic areas including hepatology with a focus on NAFLD and NASH. Founded in 2016 and headquartered in San Antonio, Texas, Pinnacle operates trial sites across San Antonio, Austin, and Georgetown with over 100 full-time employees. The partnership aims to drive organic and inorganic growth while leveraging LongueVue Capital's healthcare M&A expertise and dedicated Life Science Operating Partner Dr. Adrian Otte.PR NewswirePinnacle Clinical Research Provides Notice Of Data BreachPinnacle Clinical Research, a San Antonio-based clinical research organization specializing in Hepatological and Gastroenterological research, is notifying individuals that their protected health information may have been compromised following unauthorized access to a single company email account discovered in April 2020 and confirmed on May 8, 2020. The exposed data included names with lab results, and in some cases additional personal information such as medical history, treatment information, dates of birth, and Social Security numbers. The company has remediated the issue, reset passwords system-wide, and is offering one year of identity monitoring services at no cost to affected individuals.